

## DAFTAR PUSTAKA

1. Andreyev, H.J., Norman, A.R., Cunningham, D., Oates, J.R., and Clarke, P.A. 1998. Kirsten ras Mutations in Patients With Colorectal Cancer: the Multicenter “RASCAL” Study. *Journal of the National Cancer Institute*. 90(9): 675 – 83.
2. Anwar, S., Frayling, I.M., Scott, N.A., and Carlson, G.L. 2004. Systemic Review of Genetic Influences on The Prognosis of Colorectal Cancer. *British Journal of Surgery*. 91: 1275 – 1291.
3. Bajaj J, Diaz E, Reya T. Stem cells in cancer initiation and progression. *J Cell Biol*.
  - a. 2020;219(1):1–12.
4. Barry, E.L., Baron, J.A., Grau, M.V., et al. 2006. K-ras Mutations in Incident Sporadic Colorectal Adenomas. *American Cancer Society*. 106: 1036 – 40.
5. Calcagno, S.R., Colon, S.L., Kreinest, P.A., et al. 2008. Oncogenic K-ras Promotes Early Carcinogenesis in the mouse Proximal Colon. *Int. J Cancer*. 122: 2462 – 2470.
6. Brink, M., de Goeij, A.F., Weijenberg, M.P., et al. 2003. Molecular Epidemiology and Cancer Prevention: K-ras Oncogene Mutation in Sporadic Colorectal Cancer in The Netherlands Cohort Study. *Oxford Journals*. 24(4): 703 – 710.
7. Sa'adah S. (2018). Sistem Peredaran Darah Manusia. Jakarta



., Sano, Y., Fu Ki., et al. 2006. Depressed-Type (*O-IIC*) Colorectal Neoplasm Patients With Family History of First-Degree Relatives with Colorectal

Cancer. *World J Gastroenterol*. 21;12(1<sup>6</sup>9<sup>6</sup>): 3082 – 7.

9. Aslett, M., Aurrecochea, C., Berriman, M., Brestelli, J., Brunk, B. P., Carrington, M., ... & Wang, H. (2010). TriTrypDB: a functional genomic resource for the Trypanosomatidae. *Nucleic acids research*, 38(suppl\_1), D457-D462.
10. Kelompok kerja Adenokarsinoma Kolorektal Indonesia. 2006. : Panduan Pengelolaan Adenokarsinoma Kolorektal Revisi 2006, Jakarta.
11. Nguyen HT, Duong HQ. The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (review). *Oncol Lett*. 2018;16(1):9–18.
12. Grady WM, Markowitz SD. The Molecular Pathogenesis of Colorectal Cancer and Its Potential Application to Colorectal Cancer Screening. *Dig Dis Sci*. 2015;60(3):762–72.
13. Einspahr, J.G., Martinez, M.E., Jiang, R., At all.2006. Associations of Ki-ras Proto-oncogene Mutation and p53 gene Overexpression in Sporadic Colorectal Adenomas with Demographic and Clinicopathologic Characteristics. *Cancer Epidemiology Biomarkers and Prevention. American Association for Cancer Research*. 15:1443 – 1450.
14. B. Paty, David B. Solit; Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer. *Cancer Res* 15 July 2010; 70 (14): 5901–5911.  
<https://doi.org/10.1158/0008-5472.CAN-10-0192>



S, Hui P. KRAS mutation testing in clinical practice. *Expert Rev Mol Diagn*. 15;15(3):375–84.

16. Boyle, P., Leon, M.E.. 2002. Epidemiology of Colorectal Cancer. *British Medical Bulletin*. 64: 1-25.
17. Smith, G., Carey, F.A., Beattie, J., Wilkie, M.J., et al. 2002. Mutation in APC, Kirsten-ras and p53—Alternative Genetic Pathways to Colorectal Cancer. *Pnas*. 99(14): 9433 – 9438.



Optimized using  
trial version  
[www.balesio.com](http://www.balesio.com)